Quick Answer
A real-world study of 90,000 patients at ECO 2026 found GLP-1 drugs cut obstructive sleep apnea risk by 69%, chronic kidney disease by 30%, and heart failure by 32% — offering life-changing benefits for India's millions with obesity-related conditions.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
If you or a family member is living with obesity alongside sleep apnea, kidney disease, or heart disease, a major new study should change how you think about GLP-1 treatment. Research presented at the European Congress on Obesity 2026 (ECO 2026) in Istanbul analysed nearly 90,000 real-world patients on GLP-1 drugs and found that meaningful weight loss on these medications cuts the risk of obstructive sleep apnea by 69 percent, chronic kidney disease by 30 percent, and heart failure by 32 percent. For India — where these conditions are among the leading causes of serious illness and premature death — these findings carry enormous implications.
What the Study Found
The research was led by Professor John Wilding of the University of Liverpool and used a large United States electronic health records database covering 89,718 patients who started liraglutide, semaglutide, or tirzepatide between January 2021 and June 2024. Researchers tracked patients for an average of 11 months after the first year of treatment and compared how much weight each patient lost against their risk of developing four conditions: obstructive sleep apnea (OSA), chronic kidney disease (CKD), osteoarthritis, and heart failure.
The results were striking. Compared to patients who lost less than 5 percent of their body weight on GLP-1 drugs, those who lost 15 percent or more had a 69 percent lower risk of developing obstructive sleep apnea, a 30 percent lower risk of chronic kidney disease, a 37 percent lower risk of osteoarthritis, and a 32 percent lower risk of heart failure. Equally important, patients who gained weight while on GLP-1 drugs — about one in five in the study — faced significantly worse outcomes, including a 22 percent higher risk of sleep apnea and a 69 percent higher risk of heart failure compared to those who maintained even modest weight loss.
The study is the largest real-world analysis of its kind and reflects patients outside controlled clinical trials — people with multiple health conditions, taking multiple medications, with varying levels of adherence. That makes its conclusions especially meaningful for clinical practice.
Why Sleep Apnea Matters So Much in India
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
Obstructive sleep apnea is severely under-diagnosed in India. Estimates suggest that between 4 and 15 percent of Indian adults have significant OSA, and in people with obesity the prevalence is far higher — some studies put it above 50 percent in obese Indian men. Despite this burden, most patients in India with sleep apnea are never diagnosed, because the condition requires overnight sleep testing that is not widely available or affordable outside major cities.
Untreated sleep apnea causes fragmented sleep, daytime fatigue, poor concentration, and dramatically elevated risks of high blood pressure, heart attack, and stroke. It is also closely linked to poorly controlled diabetes — poor sleep raises blood sugar and blunts the effects of insulin. For many Indian patients managing obesity and type 2 diabetes, undiagnosed sleep apnea is an invisible factor making everything harder to control.
The ECO 2026 finding that significant weight loss on GLP-1 drugs cuts sleep apnea risk by 69 percent is therefore transformative. It means that for Indian patients with obesity who are also struggling with snoring, poor sleep, or daytime fatigue — symptoms that frequently signal undiagnosed OSA — starting GLP-1 therapy could address the root cause rather than just managing individual symptoms with separate treatments.
The Kidney Disease Connection
India has one of the highest burdens of chronic kidney disease (CKD) in the world. The Indian CKD Registry estimates that approximately 17 percent of Indian adults have some degree of CKD, and the condition is closely tied to diabetes and high blood pressure — both of which are strongly associated with obesity. Diabetes accounts for approximately 35 to 40 percent of all end-stage kidney disease requiring dialysis in India. Once kidneys reach the point of requiring dialysis, the cost of treatment — Rs 8,000 to Rs 15,000 per month — is catastrophic for most families, and outcomes are poor.
The ECO 2026 study found a 30 percent reduction in CKD risk among patients who achieved 15 percent or greater weight loss on GLP-1 drugs. This is consistent with earlier clinical trial data — the FLOW trial of semaglutide published in 2024 found a 24 percent reduction in kidney disease progression and deaths from kidney disease in patients with diabetes and existing CKD. Together, these findings establish GLP-1 drugs as nephroprotective — meaning they actively protect kidney function — in a way that few other drug classes can claim.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
For Indian patients with diabetes, high blood pressure, and excess weight, this means GLP-1 therapy is not just about losing weight. It is about protecting kidneys that are already under sustained metabolic stress, and potentially avoiding the devastating trajectory toward dialysis.
Why Staying on Treatment Matters
One of the most important findings in the ECO 2026 study was the high discontinuation rate. About half of all patients — 50 percent — stopped GLP-1 treatment within the first year, defined as a gap of at least 60 days without medication. Among patients who discontinued, the protective benefits were significantly reduced or lost entirely.
This is a critical message for Indian patients. GLP-1 drugs deliver their benefits through sustained weight loss — and sustained weight loss requires sustained treatment. The risks of stopping are real: weight regains rapidly after discontinuation, and with it come rising blood pressure, worsening blood sugar, and the reversal of the metabolic gains that were protecting the heart, kidneys, and airways. Starting GLP-1 therapy with a clear plan for long-term continuation — and access to ongoing specialist support — is essential to realising these benefits.
What Indian Patients Should Do
If you have obesity and are also managing any of the following — snoring or disrupted sleep, kidney function that has been flagged as borderline or reduced, heart disease or high blood pressure, or type 2 diabetes — GLP-1 therapy addresses multiple problems simultaneously in a way that no other treatment currently available in India can match. You do not need to wait for a single condition to worsen dramatically before acting. The evidence from real-world studies now shows that meaningful weight loss early in treatment produces the greatest and most lasting protective effects.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
A GLP-1 consultation at MySurgery includes a review of your metabolic profile, existing conditions, current medications, and kidney and cardiac health. We can advise on whether semaglutide or tirzepatide is more appropriate for your situation, what monitoring is needed during treatment, and how to build a sustainable long-term treatment plan.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. SciTechDaily — GLP-1 Weight Loss Linked To Dramatically Lower Risk of Sleep Apnea, Kidney Disease and More — https://scitechdaily.com/glp-1-weight-loss-linked-to-dramatically-lower-risk-of-sleep-apnea-kidney-disease-and-more/ 2. Heally — 5 GLP-1 trends to expect in 2026: expanded uses, oral options, and more — https://getheally.com/patients/news/5-glp-1-trends-to-expect-in-2026-expanded-uses-oral-options-and-more 3. HCPLive — Where Are We Now? Treating Chronic Kidney Disease in 2026 — https://www.hcplive.com/view/where-are-we-now-treating-chronic-kidney-disease-in-2026
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.